Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

VistaShares Marks the One-Year Anniversary of its Artificial Intelligence Supercycle ETF (AIS)

View original at globenewswire.com
VistaShares Marks the One-Year Anniversary of its Artificial Intelligence Supercycle ETF (AIS) BOSTON, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The approach behind both funds is clearly resonating with investors and advisors who understand the role that AI and electrification investments can play in a portfolio but who also understand the importance of having diversified exposure outside of the category's boldfaced names

    80% confidence
  • From day one, we knew thematic investing needed a reset. Investors should be able to invest in a major technology shift without guessing which single company will win

    80% confidence
  • Without lesser known companies around the world that might not be on investor radars, the AI revolution cannot proceed

    80% confidence
  • AIS was built to give people exposure to the full AI supply chain and the real engines of this Supercycle

    80% confidence
  • A year later, the fund has emerged as the top-performing fund in the AI Infrastructure sector

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
VistaShares Marks the One-Year Anniversary of its Artificial Intelligence Supercycle ETF (AIS) — Source | Via News | ViaNews EU